公开(公告)号：US08545847B2

公开(公告)日：2013-10-01

申请号：US13301944

申请日：2011-11-22

Applicant: Haruka Okamoto ,  Mark Sleeman ,  Joyce Harp

Inventor： Haruka Okamoto ,  Mark Sleeman ,  Joyce Harp

IPC: A61K39/00 ,  C07K16/00 ,  C12P21/08

CPC classification number: C07K16/2869 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/1137 ,  C12N15/64 ,  C12N15/70 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.

Abstract translation: 本发明提供了结合人胰高血糖素受体的称为GCGR的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人GCGR结合的完全人抗体。 本发明的抗体可用于降低血糖水平和血液酮水平，并且还可用于治疗与一种或多种GCGR生物活性相关的疾病和病症，包括治疗糖尿病，糖尿病酮症酸中毒和与之相关的长期并发症 糖尿病或其他部分由血糖水平升高表征的代谢性疾病。

公开(公告)号：US20120128679A1

公开(公告)日：2012-05-24

申请号：US13301944

申请日：2011-11-22

Applicant: Haruka Okamoto ,  Mark Sleeman ,  Joyce Harp

Inventor： Haruka Okamoto ,  Mark Sleeman ,  Joyce Harp

IPC: A61K39/395 ,  A61P3/10 ,  A61P3/08 ,  A61P3/04 ,  A61P13/12 ,  A61P3/00 ,  A61P27/02 ,  A61P27/12 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00 ,  C07K16/28 ,  A61P25/00

CPC classification number: C07K16/2869 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C12N15/1137 ,  C12N15/64 ,  C12N15/70 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.

Abstract translation: 本发明提供了结合人胰高血糖素受体的称为GCGR的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人GCGR结合的完全人抗体。 本发明的抗体可用于降低血糖水平和血液酮水平，并且还可用于治疗与一种或多种GCGR生物活性相关的疾病和病症，包括治疗糖尿病，糖尿病酮症酸中毒和与之相关的长期并发症 糖尿病或其他部分由血糖水平升高表征的代谢性疾病。

公开(公告)号：US20050096264A1

公开(公告)日：2005-05-05

申请号：US10990058

申请日：2004-11-16

Applicant: Lynn MacDonald ,  Mark Sleeman ,  Andrew Murphy

Inventor： Lynn MacDonald ,  Mark Sleeman ,  Andrew Murphy

IPC: A61K38/00 ,  C07K14/59 ,  A61K38/22

CPC classification number: C07K14/59 ,  A61K38/00

Abstract: A method of treating or ameliorating an orphan glycoprotein hormone (OGH)-related condition or a condition which responds to OGH administration, comprising administering an OGH-related compound to a subject in need thereof.

Abstract translation: 一种治疗或改善孤儿糖蛋白激素（OGH）相关病症或对OGH给药作出反应的病症的方法，包括向有需要的受试者施用OGH相关化合物。

公开(公告)号：US20050070519A1

公开(公告)日：2005-03-31

申请号：US10499230

申请日：2002-12-19

Applicant: Christopher Schofield ,  Kirsty Hewitson ,  Mark Sleeman

Inventor： Christopher Schofield ,  Kirsty Hewitson ,  Mark Sleeman

IPC: C07D205/08 ,  C07D477/04 ,  C07D503/00 ,  C12P17/10 ,  A61K31/397 ,  C12P37/00

CPC classification number: C12P17/10 ,  C07D205/08 ,  C07D477/04 ,  C07D503/00

Abstract: A process for the preparation of a substituted C-2 β-lactam comprises incubating a 2-substituted 3-aminocarboxylic acid with a β-lactam synthetase under conditions such that the 2-substituted 3-aminocarboxylic acid is cyclised to produce a substituted C-2 β-lactam. The process can be used to produce an antibiotic or β-lactamase inhibitor.

Abstract translation: 制备取代的C-2β-内酰胺的方法包括在2-取代的3-氨基羧酸环化以产生取代的C-2β-内酰胺的条件下，将2-取代的3-氨基羧酸与β-内酰胺合成酶一起温育， 2β-内酰胺。 该方法可用于产生抗生素或β-内酰胺酶抑制剂。

公开(公告)号：US20060058224A1

公开(公告)日：2006-03-16

申请号：US11229426

申请日：2005-09-15

Applicant: George Yancopoulos ,  Stanley Wiegand ,  Mark Sleeman ,  Ellen-Marie Koehler-Stec

Inventor： George Yancopoulos ,  Stanley Wiegand ,  Mark Sleeman ,  Ellen-Marie Koehler-Stec

IPC: A61K38/18 ,  A61K31/4439 ,  A61K31/426 ,  A61K31/365 ,  A61K31/155 ,  A61K31/16

CPC classification number: A61K31/155 ,  A61K31/16 ,  A61K31/365 ,  A61K31/426 ,  A61K31/4439 ,  A61K38/185 ,  A61K45/06 ,  A61K2300/00

Abstract: Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension with a combination of CNTF or a CNTF-related molecule and a second agent which is a therapeutic molecule useful in the treatment of obesity, type II diabetes, or other obesity-related conditions.

Abstract translation: 治疗肥胖或肥胖相关病症的组合物和方法，包括减轻体重，改善糖尿病参数，代谢综合征。 肝脂肪变性和/或具有CNTF或CNTF相关分子的组合的高血压和作为治疗肥胖，II型糖尿病或其它肥胖相关病症的治疗分子的第二药剂。

公开(公告)号：US20060024309A1

公开(公告)日：2006-02-02

申请号：US11193746

申请日：2005-07-29

Applicant: Jingtai Cao ,  Li-Hsien Wang ,  Hsin Lin ,  Mark Sleeman ,  Stanley Wiegand

Inventor： Jingtai Cao ,  Li-Hsien Wang ,  Hsin Lin ,  Mark Sleeman ,  Stanley Wiegand

IPC: A61K39/395 ,  A61K38/28 ,  A61K48/00

CPC classification number: A61K38/179 ,  A61K38/28 ,  A61K48/00 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14 ,  A61K2300/00

Abstract: Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.

Abstract translation: 通过阻断或抑制VEGF介导的活性来治疗哺乳动物，特别是人类的糖尿病的方法。 VEGF介导的活性的优选抑制剂是VEGF拮抗剂，例如能够结合和阻断VEGF的SEQ ID NO：2的VEGF融合蛋白捕获物。 本发明的方法可以与其它疗法组合，例如用胰岛素治疗。

公开(公告)号：US20050250185A1

公开(公告)日：2005-11-10

申请号：US11008727

申请日：2004-12-09

Applicant: Andrew Murphy ,  Lynn Macdonald ,  Mark Sleeman

Inventor： Andrew Murphy ,  Lynn Macdonald ,  Mark Sleeman

IPC: A61K48/00 ,  C07H21/04 ,  C07K14/575 ,  C07K14/59 ,  C07K16/46

CPC classification number: A61K48/005 ,  A01K2267/0362 ,  A61K38/00 ,  C07K14/575 ,  C07K14/59 ,  C07K2319/30

Abstract: A fusion polypeptide comprising an orphan glyprotein hormone (OGH), OGH-family member, or a fragment thereof; a glycoprotein hormone subunit α1 or α2, or a fragment thereof, and optionally a peptide (P), and a fusion component (F). In one embodiment, the fusion protein comprises hOGH-hFc-hα2 or hTSH-hFc-hα1.

Abstract translation: 包含孤儿糖蛋白激素（OGH），OGH家族成员或其片段的融合多肽; 糖蛋白激素亚基α1或α2或其片段，以及任选的肽（P）和融合成分（F）。 在一个实施方案中，融合蛋白包含hOGH-hFc-halpha2或hTSH-hFc-halpha1。